Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 15

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 15
---
 otherwise satisfied.

Q: What will TELO’s stockholders receive in the Merger?

A:At the Effective Time, TELO’s stockholders will continue to own and hold their existing shares of TELO Common Stock.

Q: What will happen to TELO’s options and restricted stock units in the Merger?

A: TELO stock options and TELO restricted stock units will remain outstanding and will not change in connection with the Merger.

Q: What will happen to TELI’s outstanding warrants in the Merger?

A: In addition to the shares of TELO Common Stock that will be exchanged for shares of TELI Common Stock at the Closing, Erez Aminov and Bayshore Trust, shareholders of TELI, hold 4,250,000 and 10,000,000 warrants, respectively, to purchase TELI Common Stock (the “Warrants”). The Warrants are exercisable upon FDA acceptance of an Investigational New Drug (IND) application for Telomir-1 at $2.00 per share, for a period of 10-years. At Closing, the Warrants will be converted to warrants to purchase Telomir Common Stock at similar terms as the Warrants.

Q: Who will be the directors of TELO following the Merger?

A:At the Effective Time, the post-Merger company is expected to initially consist of the four (4) current members of TELO’s board of directors, comprised of Erez Aminov, Edward MacPherson, Matthew Whalen and Matthew del Guidice.

The aforementioned board of directors will have an audit committee, a compensation committee and a nominating and corporate governance committee, in accordance with the rules of The Nasdaq Stock Market LLC (“Nasdaq”).

Q: Who will be the executive officers of TELO following the Merger?

A:Immediately following the Merger, the executive management team of the post-Merger company is expected to remain the same as TELO pre-Merger:

| Name         |     | Position          
 with TELO         |
| Erez         
 Aminov       |     | Chief             
 Executive Officer |
| Alan         
 Weichselbaum |     | Chief             
 Financial Officer |

| 6 |

Q: What risks should I consider in deciding whether to vote in favor of Proposal No. 1?

A: You should carefully review the section of the proxy statement titled “ Risk Factors,” which sets forth certain risks and uncertainties related to the Merger, risks and uncertainties